Marijuana compound tested as safer schizophrenia treatment
NCT ID NCT02926859
Summary
This study is testing whether adding cannabidiol (CBD), a non-psychoactive compound from cannabis, to standard antipsychotic medication helps people with schizophrenia stay on treatment longer and improves their symptoms. It will involve 180 people who have been diagnosed within the last seven years and are already on stable medication. The goal is to see if CBD can help control the disease with fewer side effects than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, Baden-Wurttemberg, 68159, Germany
-
Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
-
Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B, 10117, Germany
-
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich
Munich, Bavaria, 80336, Germany
-
Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne
Cologne, North Rhine-Westphalia, 50924, Germany
Conditions
Explore the condition pages connected to this study.